News
Launched AI/ML Strategy to Transform AAV Gene Therapy
Company Context
- Company Value
- $101M
- Revenue
- <$5 Million (Source: ZoomInfo, Mar 2026)
- Market
- Biotech
- Stage
- Seed
Key Highlight
Latus Bio launched with $54 million in Series A financing in May 2024 to develop gene therapies for CNS disorders.
More from Latus Bio
More Biotech News
- ColossalColossal Biosciences Reawakens the Dire WolfMar 2026
- MinicircleKlotho Gene Therapy launching in 2026Mar 2026
- ColossalColossal Foundation Doubles Funding to $100MJan 2026
- ColossalColossal Foundation raised $50 millionDec 2025
- AetherRaised $15M to reindustrialize America with AI-designed proteinsDec 2025